Tiuliandin S A, Bulanov A A, Titov D A, Sokolov A V, Sholokhov V N, Garin A M
Urol Nefrol (Mosk). 1996 Mar-Apr(2):26-9.
236 patients with nonseminomatous germ cell tumors have been treated for the last decade with VAB-6 combination and 188 ones with etoposide-containing regimens BEP and EP. Complete remissions were achieved in 97(41%) VAB-6 treated patients, 72(31%) patients were currently alive without evidence of the disease for 76 months of follow-up. Patients on BEP-EP presented better outcomes: 130(69%) of 188 patients achieved a complete remission and 119(63%) of them were free of symptoms within 47 months of follow-up. In spite of more pronounced toxicity, mainly myelosuppression, etoposide-containing combinations are more efficient than VAB-6 and should be considered as an induction chemotherapy in patients with nonseminomatous germ cell tumors.
在过去十年中,236例非精原细胞瘤性生殖细胞肿瘤患者接受了VAB - 6联合化疗,188例患者接受了含依托泊苷的化疗方案BEP和EP。接受VAB - 6治疗的97例(41%)患者实现了完全缓解,72例(31%)患者在76个月的随访中目前仍存活且无疾病证据。接受BEP - EP治疗的患者预后更佳:188例患者中有130例(69%)实现了完全缓解,其中119例(63%)在47个月的随访中无症状。尽管毒性更明显,主要是骨髓抑制,但含依托泊苷的联合化疗方案比VAB - 6更有效,应被视为非精原细胞瘤性生殖细胞肿瘤患者的诱导化疗方案。